NARA Discovery
Article Details
← Back to Search Results
Journal Article

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

Nienke Visser; Laure C. M. Herreman; Jennifer Vandooren; Rafaela Vaz Sousa Pereira; Ghislain Opdenakker; Robin E. J. Spelbrink; Maarten H. Wilbrink; Edwin Bremer; Reinoud Gosens; Martijn C. Nawijn; Heidi H. van der Ende-Metselaar; Jolanda M. Smit; Marc C. Laus; Jon D. Laman
Journal of Molecular Medicine · Vol. 102, Issue 4 · pp. 521-536 · 2024

Abstract

Viruses critically rely on various proteases to ensure host cell entry and replication. In response to viral infection, the host will induce acute tissue inflammation pulled by granulocytes. Upon hyperactivation, neutrophil granulocytes may cause undue tissue damage through proteolytic degradation of the extracellular matrix. Here, we assess the potential of protease inhibitors (PI) derived from potatoes in inhibiting viral infection and reducing tissue damage. The original full spectrum of potato PI was developed into five fractions by means of chromatography and hydrolysis. Individual fractions showed varying inhibitory efficacy towards a panel of proteases including trypsin, chymotrypsin, ACE2, elastase, and cathepsins B and L. The fractions did not interfere with SARS-CoV-2 infection of Vero E6 cells in vitro. Importantly, two of the fractions fully inhibited elastin-degrading activity of complete primary human neutrophil degranulate. These data warrant further development of potato PI fractions for biomedical purposes, including tissue damage crucial to SARS-CoV-2 pathogenesis. Key messages Protease inhibitor fractions from potato differentially inhibit a series of human proteases involved in viral replication and in tissue damage by overshoot inflammation. Protease inhibition of cell surface receptors such as ACE2 does not prevent virus infection of Vero cells in vitro. Protease inhibitors derived from potato can fully inhibit elastin-degrading primary human neutrophil proteases. Protease inhibitor fractions can be produced at high scale (hundreds of thousands of kilograms, i.e., tons) allowing economically feasible application in lower and higher income countries.

Bibliographic Information

JournalJournal of Molecular Medicine
PublisherSpringer
Publication Date2024-04-01
Publication Year2024
Volume102
Issue4
Pages521-536
Document TypeJournal Article
Print ISSN0946-2716
eISSN1432-1440
DOI10.1007/s00109-024-02423-x

Access Information

NARA Access Coverage1922-01-01~Current
Journal Homepagehttps://www.springer.com/journal/109
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.